EuroBiotech: More articles of note

Affimed received a payment from Genentech for reaching a preclinical milestone. (Pixabay)

> NeuroVive Pharmaceutical enrolled the first subject in a phase 1a/b trial of KL1333, a modulator of cellular levels of the NAD+ coenzyme. The drug could be used to treat primary genetic mitochondrial disorders. (Statement)

> Shares in Motif Bio rose more than 90% after it revealed it is meeting with the FDA to discuss the complete response letter for antibiotic iclaprim. (Release)

> Cytovation moved its treatment for HPV-induced warts into clinical development. The Norwegian biotech plans to start a second trial in malignant tumors later in the year. (Statement


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Transgene secured a €20 million credit facility from a French bank. The credit extends Transgene’s cash runway out to the middle of next year. (Release—PDF)

> Affimed received a payment from Genentech for reaching a preclinical milestone. (Statement)

> Enterome teamed up with Dana-Farber Cancer Institute to develop microbiome-derived antigens as cancer immunotherapies. The alliance gives Enterome access to the cancer institute’s preclinical models. (Release)

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.